Defining Progression Free Survival After Multiple Lines of Therapy and Impact of Dynamic Changes in FLIPI for Multiply Relapsed Follicular Lymphoma in the Rituximab Era Treated at Memorial Sloan Kettering Cancer Center (MSKCC)